These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17035456)

  • 1. The current treatment of pulmonary arterial hypertension: time to redefine success.
    Rich S
    Chest; 2006 Oct; 130(4):1198-202. PubMed ID: 17035456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors in the management of primary pulmonary hypertension.
    Jue VI
    Prog Cardiovasc Nurs; 2004; 19(2):74-9. PubMed ID: 15133384
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacologic treatment for pulmonary arterial hypertension.
    Sastry BK
    Curr Opin Cardiol; 2006 Nov; 21(6):561-8. PubMed ID: 17053404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Specific drugs for the treatment of pulmonary arterial hypertension - current status].
    Stähler G
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S183-6. PubMed ID: 18814092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary hypertension: current diagnosis and treatment.
    Rosenkranz S
    Clin Res Cardiol; 2007 Aug; 96(8):527-41. PubMed ID: 17534570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sildenafil for pulmonary hypertension.
    Lee AJ; Chiao TB; Tsang MP
    Ann Pharmacother; 2005 May; 39(5):869-84. PubMed ID: 15827074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
    Bharani A; Mathew V; Sahu A; Lunia B
    Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?
    Chapman TH; Wilde M; Sheth A; Madden BP
    Vascul Pharmacol; 2009; 51(2-3):90-5. PubMed ID: 19386283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin antagonism in pulmonary arterial hypertension.
    Lee SH; Channick RN
    Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
    Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; Ng LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS
    Am J Respir Crit Care Med; 2005 Jun; 171(11):1292-7. PubMed ID: 15750042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Izbicki G; Rosengarten D; Picard E
    N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528809
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pulmonary hypertension in left heart disease].
    Opitz CF; Gläser S; Ewert R
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S167-9. PubMed ID: 19718607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in therapeutics for pulmonary arterial hypertension.
    Wilkins MR; Møller GM; Ren X; Wharton J
    Minerva Cardioangiol; 2002 Jun; 50(3):175-87. PubMed ID: 12107399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary arterial hypertension: the race for the most effective treatment.
    McLaughin VV; Hoeper MM
    Am J Respir Crit Care Med; 2005 Jun; 171(11):1199-201. PubMed ID: 15914567
    [No Abstract]   [Full Text] [Related]  

  • 18. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Galiè N; Ghofrani HA; Torbicki A; Barst RJ; Rubin LJ; Badesch D; Fleming T; Parpia T; Burgess G; Branzi A; Grimminger F; Kurzyna M; Simonneau G;
    N Engl J Med; 2005 Nov; 353(20):2148-57. PubMed ID: 16291984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension.
    Tulloh R
    Paediatr Drugs; 2009; 11(2):115-28. PubMed ID: 19301933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.